DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

Search

Ocugen Inc

Fermé

1.78 1.71

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.76

Max

1.87

Chiffres clés

By Trading Economics

Revenu

611K

-15M

Ventes

-108K

1.4M

Marge bénéficiaire

-1,073.489

Employés

95

EBITDA

724K

-13M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+367.03% upside

Dividendes

By Dow Jones

Prochains Résultats

7 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

138M

456M

Ouverture précédente

0.07

Clôture précédente

1.78

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Ocugen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 oct. 2025, 16:58 UTC

Résultats

BMW Trims 2025 View, Citing Weaker Performance in China

7 oct. 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 oct. 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 oct. 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 oct. 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 oct. 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 oct. 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 oct. 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7 oct. 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 oct. 2025, 20:44 UTC

Actions en Tendance

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 oct. 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 oct. 2025, 19:23 UTC

Acquisitions, Fusions, Rachats

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 oct. 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 oct. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 oct. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 oct. 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 oct. 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 oct. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 oct. 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 oct. 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 oct. 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 oct. 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 oct. 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 oct. 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 oct. 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 oct. 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 oct. 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 oct. 2025, 14:52 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparaison

Variation de prix

Ocugen Inc prévision

Objectif de Prix

By TipRanks

367.03% hausse

Prévisions sur 12 Mois

Moyen 8.5 USD  367.03%

Haut 15 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.6818 / 0.74Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat